Article · 9 Jan 2025
Conference abstractPublished 10 Aug 2017
Biosimilars: Accelerating early clinical development
Vice Precident, Quintiles IMS, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
This presentation will discuss how early clinical development with biosimilars is paramount to later development and registration success. It will provide an overview of ECD services successfully used for implementing Phase-I biosimilar trials in Asia Pacific as well as the West (e.g., US and EU) for global registrations. It will present an overview of site selection and feasibility data using a Next Generation approach driven by IMS legacy data to aid recruitment especially in tough areas to recruit patients for biosimilar trials such as the US and Europe. Finally, a model to accelerated biosimilar development will be presented that has been successfully used by one of the world’s largest providers of pharmaceutical services.
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 27 Aug 2022
The end of Phase 3 clinical trials in biosimilars development?
Conference abstract · 10 Aug 2017
Clinical development of biosimilars for Western markets: Planning for success
Conference abstract · 26 Oct 2015
Issues in the Clinical Development of the first Wave of Biosimilars
Conference abstract · 27 Oct 2014
Challenges and its resolutions in the conduct of biosimilars clinical development
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Raymond Huml”
